Changeflow GovPing Pharma & Drug Safety Nestlé RECOVER Dietary Supplement Patent - Ther...
Routine Notice Added Final

Nestlé RECOVER Dietary Supplement Patent - Therapeutic Applications

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published March 25th, 2026
Detected April 2nd, 2026
Email

Summary

The European Patent Office published Patent EP3976088A1 for Nestlé S.A.'s RECOVER dietary supplement. The patent covers compositions including vitamins, minerals, and amino acids for therapeutic applications, particularly muscle function support (A61P 21/00). The patent is designated for all 31 European member states and extension countries.

What changed

The European Patent Office granted Patent EP3976088A1 to Nestlé S.A. for the RECOVER dietary supplement composition. The patent claims a combination of active ingredients including B vitamins (thiamine, riboflavin, niacin, B6, folate, B12), vitamin C, zinc, magnesium, selenium, and amino acids. The designated states include all major European markets (AL, AT, BE, DE, ES, FR, GB, IT, NL, PL, etc.).

Patent publications do not create compliance obligations for third parties. Competitors developing similar dietary supplement formulations should review the patent claims to assess potential infringement risks. No immediate action is required unless pursuing related product development in designated European territories.

Source document (simplified)

← EPO Patent Bulletin

RECOVER DIETARY SUPPLEMENT

Publication EP3976088A1 Kind: A1 Mar 25, 2026

Applicants

Société des Produits Nestlé S.A.

Inventors

SEIDENSTICKER, Kurt, APORTA, Matt, FRIESE, Corey, SKUBAL, Angela

IPC Classifications

A61K 38/39 20060101AFI20230907BHEP A61K 33/30 20060101ALI20230907BHEP A61K 33/06 20060101ALI20230907BHEP A61K 33/04 20060101ALI20230907BHEP A61K 33/00 20060101ALI20230907BHEP A61K 31/675 20060101ALI20230907BHEP A61K 31/525 20060101ALI20230907BHEP A61K 31/51 20060101ALI20230907BHEP A61K 31/455 20060101ALI20230907BHEP A61K 31/375 20060101ALI20230907BHEP A61K 31/198 20060101ALI20230907BHEP A61K 31/185 20060101ALI20230907BHEP A23L 33/17 20160101ALI20230907BHEP A23L 33/16 20160101ALI20230907BHEP A23L 33/15 20160101ALI20230907BHEP A23L 2/39 20060101ALI20230907BHEP A61K 38/01 20060101ALI20230907BHEP A23L 33/18 20160101ALI20230907BHEP A23L 33/175 20160101ALI20230907BHEP A61P 21/00 20060101ALI20230907BHEP A61K 31/519 20060101ALI20230907BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

A61P 21/00 - Muscle Disorders A23L 33/17 - Food Proteins A23L 33/16 - Food Enzymes A23L 33/15 - Food Vitamins

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3976088A1

Who this affects

Applies to
Food manufacturers Pharmaceutical companies
Industry sector
3114 Food & Beverage Manufacturing 3254 Pharmaceutical Manufacturing
Activity scope
Patent Protection Dietary Supplement Composition Therapeutic Applications
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Consumer Protection

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.